Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

By N. Viney, J. V. van Capelleveen, R. Geary, S. Xia, J. Tami, R. Yu, Santica M. Marcovina, S. Hughes, M. Graham, R. Crooke and 4 more. The Lancet, 2016

686 citations recorded by the source corpus.

Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/c0be8b2c33496daa8fac914001697e46b9f32309

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Marja-Riitta Taskinen
2. I. Graham
3. S. Tsimikas
4. Ulrich Laufs

In Endocrinology, Diabetes and Metabolism

1. S. Tsimikas
2. Marja-Riitta Taskinen
3. I. Graham
4. Alberico L. Catapano
5. Rhian M. Touyz

In Surgery

1. S. Tsimikas
2. I. Graham
3. Marja-Riitta Taskinen
4. Alberico L. Catapano
5. Ulrich Laufs

Citations in the corpus

• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “Results from studies of an antisense oligonucleotide in patients with normal Lp(a) values as well as in patients with elevated Lp(a) concentrations have shown a reduction of >90%.(352) These approaches are currently being evaluated in phase II III studies and an outcome trial is planned to study whe”
• A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. (2017, background): “Recently, optimized ASOs to apo(a) have been reported for human trials (78), and 3 randomized, controlled trials (29,62) have reported dosedependent reductions in mean Lp(a) lowering of >80%.”